Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 11/7, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (Rm. 1503), 10903 New Hampshire Ave., Silver Spring, MD. The committee will discuss the safety and efficacy of a Novartis Pharmaceuticals NDA for Signifor (pasireotide injection) for subcutaneous administration, an analog of somatostatin, for treating patients with Cushing’s disease who require medical intervention. Contact Paul Tran, (301) 796-9001. To view this notice, click here.